Phosphodiesterase type 4 expression and anti-proliferative effects in human pulmonary artery smooth muscle cells

被引:40
作者
Growcott, EJ
Spink, KG
Ren, XH
Afzal, S
Banner, KH
Wharton, J
机构
[1] Univ London Imperial Coll Sci Technol & Med, Sect Expt Med & Toxicol, London W12 0NN, England
[2] Pfizer Global Res & Dev, Discovery Biol, Sandwich CT13 9NJ, Kent, England
[3] Inst Psychiat, MRC London Neurodegenerat Dis Brain Bank, London SE5 8AF, England
[4] Novartis Inst Biomed Res, Horsham RH12 5AB, W Sussex, England
关键词
D O I
10.1186/1465-9921-7-9
中图分类号
R56 [呼吸系及胸部疾病];
学科分类号
摘要
Background: Pulmonary arterial hypertension is a proliferative vascular disease, characterized by aberrant regulation of smooth muscle cell proliferation and apoptosis in distal pulmonary arteries. Prostacyclin (PGI(2)) analogues have anti-proliferative effects on distal human pulmonary artery smooth muscle cells (PASMCs), which are dependent on intracellular cAMP stimulation. We therefore sought to investigate the involvement of the main cAMP-specific enzymes, phosphodiesterase type 4 (PDE4), responsible for cAMP hydrolysis. Methods: Distal human PASMCs were derived from pulmonary arteries by explant culture (n = 14, passage 3-12). Responses to platelet-derived growth factor-BB (5-10 ng/ml), serum, PGI(2) analogues (cicaprost, iloprost) and PDE4 inhibitors (roflumilast, rolipram, cilomilast) were determined by measuring cAMP phosphodiesterase activity, intracellular cAMP levels, DNA synthesis, apoptosis (as measured by DNA fragmentation and nuclear condensation) and matrix metalloproteinase-2 and -9 (MMP-2, MMP-9) production. Results: Expression of all four PDE4A-D genes was detected in PASMC isolates. PDE4 contributed to the main proportion (35.9 +/- 2.3%, n = 5) of cAMP-specific hydrolytic activity demonstrated in PASMCs, compared to PDE3 (21.5 +/- 2.5%), PDE2 (15.8 +/- 3.4%) or PDE1 activity (14.5 +/- 4.2%). Intracellular cAMP levels were increased by PGI(2) analogues and further elevated in cells co-treated with roflumilast, rolipram and cilomilast. DNA synthesis was attenuated by 1 mu M roflumilast (49 +/- 6% inhibition), rolipram (37 +/- 6%) and cilomilast (30 +/- 4%) and, in the presence of 5 nM cicaprost, these compounds exhibited EC50 values of 4.4 (2.6-6.1) nM (Mean and 95% confidence interval), 59 (36 -83) nM and 97 (66-130) nM respectively. Roflumilast attenuated cell proliferation and gelatinase (MMP-2 and MMP- 9) production and promoted the anti-proliferative effects of PGI(2) analogues. The cAMP activators iloprost and forskolin also induced apoptosis, whereas roflumilast had no significant effect. Conclusion: PDE4 enzymes are expressed in distal human PASMCs and the effects of cAMP-stimulating agents on DNA synthesis, proliferation and MMP production is dependent, at least in part, on PDE4 activity. PDE4 inhibition may provide greater control of cAMP-mediated anti-proliferative effects in human PASMCs and therefore could prove useful as an additional therapy for pulmonary arterial hypertension.
引用
收藏
页数:12
相关论文
共 53 条
[1]   Differential type 4 cAMP-specific phosphodiesterase (PDE4) expression and functional sensitivity to PDE4 inhibitors among rats, monkeys and humans [J].
Bian, H ;
Zhang, J ;
Wu, P ;
Varty, LA ;
Jia, YL ;
Mayhood, T ;
Hey, JA ;
Wang, P .
BIOCHEMICAL PHARMACOLOGY, 2004, 68 (11) :2229-2236
[2]  
Bundschuh DS, 2001, J PHARMACOL EXP THER, V297, P280
[3]   Ursolic acid-induced down-regulation of MMP-9 gene is mediated through the nuclear translocation of glucocorticoid receptor in HT1080 human fibrosarcoma cells [J].
Cha, HJ ;
Park, MT ;
Chung, HY ;
Kim, ND ;
Sato, H ;
Seiki, M ;
Kim, KW .
ONCOGENE, 1998, 16 (06) :771-778
[4]   Differential effects of stable prostacyclin analogs on smooth muscle proliferation and cyclic AMP generation in human pulmonary artery [J].
Clapp, LH ;
Finney, P ;
Turcato, S ;
Tran, S ;
Rubin, LJ ;
Tinker, A .
AMERICAN JOURNAL OF RESPIRATORY CELL AND MOLECULAR BIOLOGY, 2002, 26 (02) :194-201
[5]   Regression of hypertrophied rat pulmonary arteries in organ culture is associated with suppression of proteolytic activity, inhibition of tenascin-C, and smooth muscle cell apoptosis [J].
Cowan, KN ;
Jones, PL ;
Rabinovitch, M .
CIRCULATION RESEARCH, 1999, 84 (10) :1223-1233
[6]   Gelatinase expression in pulmonary arteries during experimental pulmonary hypertension [J].
Frisdal, E ;
Gest, V ;
Vieillard-Baron, A ;
Levame, M ;
Lepetit, H ;
Eddahibi, S ;
Lafuma, C ;
Harf, A ;
Adnot, S ;
d'Ortho, MP .
EUROPEAN RESPIRATORY JOURNAL, 2001, 18 (05) :838-845
[7]   Life after PDE4: overcoming adverse events with dual-specificity phosphodiesterase inhibitors [J].
Giembycz, MA .
CURRENT OPINION IN PHARMACOLOGY, 2005, 5 (03) :238-244
[8]   Cyclic AMP-mobilizing agents and glucocorticoids modulate human smooth muscle cell migration [J].
Goncharova, EA ;
Billington, CK ;
Irani, C ;
Vorotnikov, AV ;
Tkachuk, VA ;
Penn, RB ;
Krymskaya, VP ;
Panettieri, RA .
AMERICAN JOURNAL OF RESPIRATORY CELL AND MOLECULAR BIOLOGY, 2003, 29 (01) :19-27
[9]  
Hatzelmann A, 2001, J PHARMACOL EXP THER, V297, P267
[10]   Cyclic AMP inhibited proliferation of human aortic vascular smooth muscle cells, accompanied by induction of p53 and p21 [J].
Hayashi, S ;
Morishita, R ;
Matsushita, H ;
Nakagami, H ;
Taniyama, Y ;
Nakamura, T ;
Aoki, M ;
Yamamoto, K ;
Higaki, J ;
Ogihara, T .
HYPERTENSION, 2000, 35 (01) :237-243